Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study of HX009+IN10018 in Patients With Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated With or Without Standard Chemotherapy

NCT06708663 is registered in ClinicalTrials.gov with Hangzhou Hanx Biopharmaceuticals, Ltd. as lead sponsor.

NCT NCT06708663
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06708663 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study of HX009+IN10018 in Patients With Advanced Solid Tumours, Including Biliary Tract Malignancies and Malignant Melanoma, Treated With or Without Standard Chemotherapy
Lead sponsor
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
January 17, 2025
Completion date
December 31, 2028
Enrollment
124 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer, melanoma